Abstract
Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m2 tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.
Original language | English (US) |
---|---|
Pages (from-to) | 171-173 |
Number of pages | 3 |
Journal | Investigational New Drugs |
Volume | 16 |
Issue number | 2 |
DOIs | |
State | Published - 1998 |
Keywords
- Hepatocellular carcinoma
- Hepatoma
- Retinoic acid
- Vitamin A
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology